|
Daily Medical Update
Lyme disease
Friday, August 28, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Infectious diseases now (2025) - Practice Guideline
Key Findings
- In early localized erythema migrans, clinical diagnosis is reliable while laboratory sensitivity is reduced, making serology unnecessary.
- Intrathecal antibody synthesis has greater than 99% sensitivity for Lyme neuroborreliosis after 6–8 weeks; negative initial serology in symptoms lasting less than 6 weeks should be repeated after 3 weeks.
📋 Practice Implication: Use a clinical diagnosis for classic erythema migrans, reserve two-tier serology for compatible disseminated disease, and interpret results in clinical context.
|
Infectious diseases now (2025) - Practice Guideline
Key Findings
- Erythema migrans accounts for approximately 80% of Lyme borreliosis cases in France and typically resolves within 15 days of antibiotic therapy.
- Neuroborreliosis occurs in approximately 6–15% of French cases and generally has favorable outcomes with antibiotic treatment, although persistent post-infectious symptoms may occur.
📋 Practice Implication: Recognize the painless expanding erythema migrans lesion and assess for disseminated skin, neurologic, joint, cardiac, or ocular involvement when the presentation is atypical.
|
Infectious diseases now (2025) - Practice Guideline
Key Findings
- PTLDS is characterized by fatigue, diffuse pain, and cognitive dysfunction lasting more than 6 months after documented and adequately treated Lyme borreliosis, with reduced daily functioning and quality of life.
- Additional antibiotic or immunomodulatory therapies do not improve PTLDS outcomes and may cause adverse effects, so they are not recommended.
📋 Practice Implication: Reassess the original diagnosis and alternative causes, then prioritize personalized rehabilitation and psychological support rather than prolonged antimicrobial therapy.
|
The Lancet. Infectious diseases (2025) - Randomized Controlled Trial
Key Findings
- One month after the month-18 booster, OspA-specific IgG geometric mean titres increased to levels exceeding post-primary-series levels in both VLA15 schedules, with higher titres in pediatric cohorts than adults.
- The booster’s tolerability profile was similar to the primary doses; related unsolicited adverse events occurred in 1% of VLA15 recipients, all resolved without sequelae, and no deaths were reported through month 19.
📋 Practice Implication: The booster data support continued evaluation of VLA15 as a pre-season prevention strategy while counseling that the candidate remains investigational and may cause short-term reactogenicity.
|
Journal of clinical microbiology (2026) - Comment
Key Findings
- Modified two-tiered testing demonstrated increased sensitivity compared with standard two-tiered testing for antibodies in early Lyme disease samples.
- Despite the sensitivity gain, early-infection sensitivity remains reduced and serology cannot distinguish active infection from past infection.
📋 Practice Implication: Modified two-tier testing may improve early-case detection, but a positive result still requires clinical interpretation and cannot by itself establish active disease.
|
|
💡
Summary
Recent Lyme disease guidance emphasizes stage-specific diagnosis: classic erythema migrans is diagnosed clinically, whereas disseminated disease requires appropriately interpreted serology and, for neuroborreliosis, cerebrospinal-fluid antibody assessment. Persistent symptoms after adequate treatment should prompt reassessment and multidisciplinary symptom-focused care rather than additional antibiotics; prevention data show robust booster responses with the investigational VLA15 vaccine, while modified two-tier serology improves early sensitivity but cannot distinguish active from past infection.
|
|